NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod (HY-B0180)-induced psoriasis in mice[1].
in vivo
NJK14047 (2.5 mg/kg, i.p. for 7-21 days) ameliorates the collage-induced rehumatoid arthritis (CIA) in DBA-1J mice and Imiquimod (HY-B0180)-induced psoriasis (IIP) in BALB/c mice, suppresses the cytokines expressions of Th1, Th2, Th17 and Treg[1].
Animal Model:
collage-induced rehumatoid arthritis in DBA-1J mice and imiquimod-induced psoriasis in BALB/c mice[1]
Dosage:
2.5 mg/kg
Administration:
i.p. for 7 days for IIP-administrated BALB/c mice, i.p. for 21 days for CIA-administrated CBA-1J mice
Result:
Ameliorated the collage-induced arthritis and CIA caused cartilage damage, inflammation, pannus formation, bone corrosion, and synovial hyperplasia.
Ameliorated the imiquimod induced psoriasis and IIP caused keratinocyte proliferation.
References
[1] Lee JH, et al., NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation. Int Immunopharmacol. 2024 Mar 30;130:111800. DOI:10.1016/j.intimp.2024.111800
